Benefits of combined preventive therapy with co-trimoxazole and isoniazid in adults living with HIV: time to consider a fixed-dose, single tablet coformulation-Reference-Cited by-同舟云学术

Benefits of combined preventive therapy with co-trimoxazole and isoniazid in adults living with HIV: time to consider a fixed-dose, single tablet coformulation

Published:2015-12 Issue:12 Volume:15 Page:1492-1496
ISSN:1473-3099
Container-title:The Lancet Infectious Diseases
language:en
Short-container-title:The Lancet Infectious Diseases

Author:

Harries Anthony D,Lawn Stephen D,Suthar Amitabh B,Granich Reuben

Funder

Wellcome Trust, London, UK

UK Department for International Development, Wellcome Trust Global Clinical Trials Grant

Publisher

Elsevier BV

Subject

Infectious Diseases

Reference40 articles.

1. Global update on the health sector response to HIV, 2014,2014

2. Prevention of HIV-1 infection with early antiretroviral therapy;Cohen;N Engl J Med,2011

3. Consolidated guidelines on the use of antiretroviral drugs for treating and preventing HIV infection: recommendations for a public health approach,2013

4. Realizing the potential of treatment as prevention: global ART policy and treatment coverage;Gupta;Curr HIV/AIDS Rep,2014

5. Trends in CD4 count at presentation to care and treatment initiation in sub-Saharan Africa, 2002–2013: a meta-analysis;Siedner;Clin Infect Dis,2015

Cited by 21 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Factors associated with isoniazid preventive treatment interruption and completion among PLHIV in Gombe Hospital, Uganda, 2017–2019;Journal of Clinical Tuberculosis and Other Mycobacterial Diseases;2023-05

2. Trends of Fixed-Dose Combination Antibiotic Consumption in Hospitals in China: Analysis of Data from the Center for Antibacterial Surveillance, 2013–2019;Antibiotics;2022-07-15

3. Factors affecting uptake and completion of isoniazid preventive therapy among HIV-infected children at a national referral hospital, Kenya: a mixed quantitative and qualitative study;BMC Infectious Diseases;2020-04-21

4. Fixed dose drug combinations – are they pharmacoeconomically sound? Findings and implications especially for lower- and middle-income countries;Expert Review of Pharmacoeconomics & Outcomes Research;2020-01-02

5. New opportunities in tuberculosis prevention: implications for people living with HIV;Journal of the International AIDS Society;2020-01